Oaktop Capital Management II’s Accelerate Diagnostics AXDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q1
Sell
-15,500
Closed -$1.18M 18
2020
Q4
$1.18M Hold
15,500
0.21% 17
2020
Q3
$1.65M Hold
15,500
0.37% 17
2020
Q2
$2.35M Hold
15,500
0.55% 16
2020
Q1
$1.29M Hold
15,500
0.4% 18
2019
Q4
$2.62M Hold
15,500
0.69% 14
2019
Q3
$2.88M Hold
15,500
0.59% 13
2019
Q2
$3.55M Hold
15,500
0.76% 14
2019
Q1
$3.26M Hold
15,500
0.68% 14
2018
Q4
$1.78M Hold
15,500
0.5% 14
2018
Q3
$3.56M Hold
15,500
0.79% 14
2018
Q2
$3.46M Hold
15,500
0.76% 14
2018
Q1
$3.54M Hold
15,500
0.74% 14
2017
Q4
$4.06M Hold
15,500
0.82% 14
2017
Q3
$3.48M Hold
15,500
0.58% 16
2017
Q2
$4.24M Hold
15,500
0.78% 16
2017
Q1
$3.75M Buy
15,500
+2,500
+19% +$571K 0.74% 16
2016
Q4
$2.7M Buy
13,000
+500
+4% +$119K 0.59% 16
2016
Q3
$3.41M Hold
12,500
0.8% 16
2016
Q2
$1.8M Buy
+12,500
New +$1.68M 0.44% 16

Other funds holding AXDX

Oaktop Capital Management II's AXDX Position: Q1 2021 in Review

Oaktop Capital Management II sold out of Accelerate Diagnostics (AXDX) in Q1 2021, closing a stake of 15,500 shares — an estimated $1.18M sold.

Oaktop Capital Management II first reported a position in AXDX in Q2 2016 and held it in 19 quarters. The position peaked at $4.24M in Q2 2017. 99 funds tracked by Wall St. Rank hold AXDX as of Q1 2021.

  • Oaktop Capital Management II reported no remaining Accelerate Diagnostics position as of Q1 2021 after selling out during the quarter.
  • Oaktop Capital Management II sold 15,500 Accelerate Diagnostics shares in Q1 2021, an estimated $1.18M.
  • Oaktop Capital Management II first reported a position in Accelerate Diagnostics in Q2 2016 and held it in 19 quarters.
  • Oaktop Capital Management II's Accelerate Diagnostics position peaked at $4.24M in Q2 2017.
  • 99 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2021.

Based on Oaktop Capital Management II's 13F filing for Q1 2021, filed 17 May 2021.